Not Yet Recruiting
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants
NCT07505030
- Conditions
- Colitis, Colitis, Ulcerative, Colonic Diseases, +6 more
- Locations
-
- CMAX Clinical Research Pty Ltd Adelaide, South Australia, Australia